Advances in management of movement disorders in children

被引:65
作者
Koy, Anne [1 ,2 ]
Lin, Jean-Pierre [3 ]
Sanger, Terence D. [4 ]
Marks, Warren A. [5 ]
Mink, Jonathan W. [6 ]
Timmermann, Lars [1 ]
机构
[1] Univ Cologne, Dept Neurol, D-50931 Cologne, Germany
[2] Univ Cologne, Dept Paediat, D-50924 Cologne, Germany
[3] Guys & St Thomas NHS Fdn Trust, Evelina Childrens Hosp, London, England
[4] Univ So Calif, Los Angeles, CA USA
[5] Cook Childrens Med Ctr, Ft Worth, TX USA
[6] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
关键词
DEEP BRAIN-STIMULATION; GUIDELINE DEVELOPMENT SUBCOMMITTEE; EUROPEAN CLINICAL GUIDELINES; DYSTONIC CEREBRAL-PALSY; BASAL GANGLIA DISEASE; TOURETTE-SYNDROME; BOTULINUM-TOXIN; PHARMACOLOGICAL-TREATMENT; AMERICAN ACADEMY; ALTERNATING HEMIPLEGIA;
D O I
10.1016/S1474-4422(16)00132-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Movement disorders in children are causally and clinically heterogeneous and present in a challenging developmental context. Treatment options are broad ranging, from pharmacotherapy to invasive neuromodulation and experimental gene and stem cell therapies. The clinical effects of these therapies are variable and often poorly sustained, and only a few of the management strategies used in paediatric populations have been tested in randomised controlled studies with age-appropriate cohorts. Identification of the most appropriate treatment is uniquely challenging in children because of the incomplete knowledge about the pathophysiology of movement disorders and their influence on normal motor development; thus, effective therapeutic options for these children remain an unmet need. It is vital to transfer the expanding knowledge of the movement disorders into the development of novel symptomatic or, ideally, disease modifying treatments, and to assess these therapeutic strategies in appropriately designed and well done trials.
引用
收藏
页码:719 / 735
页数:17
相关论文
共 131 条
[1]   The clinical approach to movement disorders [J].
Abdo, Wilson F. ;
van de Warrenburg, Bart P. C. ;
Burn, David J. ;
Quinn, Niall P. ;
Bloem, Bastiaan R. .
NATURE REVIEWS NEUROLOGY, 2010, 6 (01) :29-37
[2]   Deep brain stimulation in children: experience and technical pearls Clinical article [J].
Air, Ellen L. ;
Ostrem, Jill L. ;
Sanger, Terence D. ;
Starr, Philip A. .
JOURNAL OF NEUROSURGERY-PEDIATRICS, 2011, 8 (06) :566-574
[3]   Phenomenology and classification of dystonia: A consensus update [J].
Albanese, Alberto ;
Bhatia, Kailash ;
Bressman, Susan B. ;
DeLong, Mahlon R. ;
Fahn, Stanley ;
Fung, Victor S. C. ;
Hallett, Mark ;
Jankovic, Joseph ;
Jinnah, Hyder A. ;
Klein, Christine ;
Lang, Anthony E. ;
Mink, Jonathan W. ;
Teller, Jan K. .
MOVEMENT DISORDERS, 2013, 28 (07) :863-873
[4]   Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases [J].
Alfadhel, Majid ;
Almuntashri, Makki ;
Jadah, Raafat H. ;
Bashiri, Fahad A. ;
Al Rifai, Muhammad Talal ;
Al Shalaan, Hisham ;
Al Balwi, Mohammed ;
Al Rumayan, Ahmed ;
Eyaid, Wafaa ;
Al-Twaijri, Waleed .
ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
[5]   Status dystonicus: a practice guide [J].
Allen, Nicholas M. ;
Lin, Jean-Pierre ;
Lynch, Tim ;
King, Mary D. .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2014, 56 (02) :105-112
[6]   Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes [J].
Andrews, Caroline ;
Aviles-Olmos, Iciar ;
Hariz, Marwan ;
Foltynie, Thomas .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (12) :1383-1389
[7]  
[Anonymous], COCHRANE DATABASE SY
[8]   Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease Report of the Guideline Development Subcommittee of the American Academy of Neurology [J].
Armstrong, Melissa J. ;
Miyasaki, Janis M. .
NEUROLOGY, 2012, 79 (06) :597-603
[9]   Movement disorders in autoimmune diseases [J].
Baizabal-Carvallo, Jose Fidel ;
Jankovic, Joseph .
MOVEMENT DISORDERS, 2012, 27 (08) :935-946
[10]   Safety profile and efficacy of botulinum toxin A (Dysporta) in children with muscle spasticity [J].
Bakheit, AMO ;
Severa, S ;
Cosgrove, A ;
Morton, R ;
Rousso, SH ;
Doderlein, L ;
Lin, JP .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2001, 43 (04) :234-238